Verastem (VSTM) Profit After Tax (2011 - 2026)
Verastem (VSTM) posted quarterly Profit After Tax of -$36.6 million for Q1 2026, up 29.77% year-over-year from -$28.2 million in Q1 2025, and down 20.48% quarter-over-quarter from -$30.4 million in Q4 2025.
Powered by 
Analysis
Verastem (VSTM) Profit After Tax (2011 - 2026) Analysis & Trends
Verastem's Profit After Tax history runs 16 years deep, the most recent figure standing at -$36.6 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 29.77% year-over-year to -$36.6 million; the TTM figure through Mar 2026 stood at -$191.4 million (down 28.57% YoY), while the FY2025 annual figure was -$209.5 million, down 60.33% from the prior year.
- Profit After Tax for Q1 2026 stood at -$36.6 million, down from -$30.4 million in the prior quarter.
- The five-year high for Profit After Tax was -$8.3 million in Q2 2024, with the low at -$98.5 million in Q3 2025.
- The 5-year median for Profit After Tax is -$24.3 million (2023), against an average of -$31.5 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 66.0% in 2024, then plunged 311.06% in 2025.
- Verastem's Profit After Tax stood at -$16.8 million in 2022, then sank by 62.5% to -$27.4 million in 2023, then sank by 135.86% to -$64.6 million in 2024, then jumped by 52.95% to -$30.4 million in 2025, then dropped by 20.48% to -$36.6 million in 2026.
- Business Quant data shows VSTM's Profit After Tax at -$36.6 million in Q1 2026, -$30.4 million in Q4 2025, and -$98.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Verastem | 800.93 Mn | 664.58 Mn | 36.32 Mn | -35.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35.25 Mn |
| Mar 31, 2026 | -36.59 Mn |
| Dec 31, 2025 | -30.37 Mn |
| Sep 30, 2025 | -98.52 Mn |
| Jun 30, 2025 | -25.93 Mn |
| Mar 31, 2025 | -52.10 Mn |
| Dec 31, 2024 | -64.55 Mn |
| Sep 30, 2024 | -23.97 Mn |
| Jun 30, 2024 | -8.26 Mn |
| Mar 31, 2024 | -33.86 Mn |
| Dec 31, 2023 | -27.37 Mn |
| Sep 30, 2023 | -20.00 Mn |
| Jun 30, 2023 | -24.28 Mn |
| Mar 31, 2023 | -15.71 Mn |
| Dec 31, 2022 | -16.77 Mn |
| Sep 30, 2022 | -18.09 Mn |
| Jun 30, 2022 | -21.95 Mn |
| Mar 31, 2022 | -16.96 Mn |
| Dec 31, 2021 | -16.47 Mn |
| Sep 30, 2021 | -22.80 Mn |